Broadcast Live   |   Upload & Publish  | About  | Register  | Sign in
E-mail:
Password:
Remember me on this computer
You need to install or upgrade your Flash Player!

3B NEXUS video platform & portal supports the latest version of Macromedia Flash player.


3B PLAYER by 3B NEXUS

Close [ X ]
Copy this code to embed & stream this video on your website
 
Copy this URL to share or create a link back to this video
Dr. Ulrich Dauer
Chief Executive Officer
Germany
4SC Resminostat – a novel epigenetic therapy to treat solid cancers in advanced clinical development
Resminostat, recently met the primary endpoint in a Phase II study in advanced liver cancer. The therapy mediates tumour cell “resensitisation” with a novel epigenetic mode of action. Resensitisation can suppress or reverse drug tolerance mechanisms that tumour cells can develop against cancer drugs. The supplementary administration of resminostat can enable the effective treatment of patients with cancer drugs to which patient response is no longer adequate.

[ close ] 
Please select the appropriate option to comply with legal regulations

Individual Investor Professional Investor or Financial Advisor
This multimedia channel includes videos, webcasts and live broadcasts suitable for members of the general public over 18 years of age and not engaged in providing investment advice. Access this channel for personal interest & information only. This multimedia channel includes investor videos and webcast presentations, live broadcasts and documents intended only for authorised and regulated professionals and financial advisers eligible to provide investment advice to private investors.
I comply with these terms I comply with these terms
Remember my choice for all channels on this portal Enter Media Channel »
No reliance should be placed on the information on this site which may change without notice.
You should read the Terms & Conditions section before browsing this site.

Search in Sort By
1 2 3 4 of 4   MORE   SHOW
  Select a title or search in slides to skip chapters
00:00
Resminostat, 4SC AG: Dr. Ulrich Dauer, CEO, 4SC AG presents, Resminostat
00:32
Forward looking statements, Forward looking statements
00:40
revenue, research collaborations, investors, cash reserves, Market cap, Liquid assets, Phase IIb study, oncology, 4SC at a glance
02:02
Pipeline, Product, Indication, Mode, Preclinical, Phase I, Phase II, Phase III, Vidofludimus, A broad and value-focused Pipeline
02:40
Resminostat, Oncology, Resminostat - A innovative epigenetic therapeutic option in oncology
03:05
press release, JANUARY 19, 2012: Pressemitteilung
03:40
Efficacy Assessment, JANUARY 19, 2012: Efficacy Assessment
04:10
chart, JANUARY 19, 2012: Chart Data
04:35
HCC, Therapy, liver cancer, 2ND LINE THERAPY, Liver cancer (HCC): high medical need
05:58
DNA, Epigenetics, About Epigenetics: why our DNA isn't our destiny
07:05
HDACs, DRUG TOLERANCE, EPIGENETIC MODIFICATION, apoptosis, SHELTER RATIONALE: HDACs PROMOTE DRUG TOLERANCE THROUGH EPIGENETIC MODIFICATION
08:53
EPIGENETIC HDAC-INHIBITION, RESMINOSTAT, Sorafenib, , SHELTER RATIONALE: RE-SENSITISATION THROUGH EPIGENETIC HDAC-INHIBITION WITH RESMINOSTAT
09:29
PHASE II, STUDY DESIGN, HCC, PHASE II
10:35
SHELTER, PRIMARY ENDPOINT MET (PFSR), Progression Free Survival (PFS) Rates and PFS, SHELTER: PRIMARY ENDPOINT MET (PFSR)
11:18
SHELTER: PROGRESSION FREE SURVIVAL (4.6 MONTHS), Mono Therapy, Combination, , SHELTER: PROGRESSION FREE SURVIVAL (4.6 MONTHS)
11:32
SHELTER CONCLUSION: SURVIVAL BENEFIT INDICATED, Placebo, Sorafenib, SHELTER CONCLUSION: SURVIVAL BENEFIT INDICATED
12:32
approval, launch, Phase II PoC, Exploratory, Road to approval - 1st launch possible in 2016/17
13:21
Resminostat, Yakult HonSHa, License Agreement, Hepatocellular carcinoma, irinotecan and oxaliplatin, Resminostat - Yakult HonSHa Partner for Japan
14:14
Clinical Development Strategy, Phase I, INDICATIONS, Hodgkin‟s Lymphoma, Hepatocellular Carcinoma, Colorectal Cancer, monotherapy, Resminostat: Clinical Development Strategy
14:53
4SC Outlook, milestones, ACHIEVEMENTS, MILESTONES, Initiate Phase IIb, , 4SC Outlook: achieved & upcoming milestones
15:50
, Company Contact